# Hangzhou Regenovo Biotechnology.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-regenovo-biotechnology

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.regenovo.com
- Latest round: Series B (Jul 2, 2018)
- Investors on record: 7

## About

Established in 2013 and based in Hangzhou, China, Hangzhou Regenovo Biotechnology., Ltd. is a biotechnology company that focuses on the research and development of 3D printing technology in the biomedical field, which won the Vice Chairman Unit of China 3D Printing Technology Industry Alliance, Vice Chairman Unit of Zhejiang Translational Medicine Association, and so on. It has established partnerships with Peking University, OLAY, Fan Beauty Secret, etc. In September 2020, Hangzhou Regenovo Biotechnology., Ltd. raised strategic investment from new investors Proya and Zheshang Venture Capital.

The company is committed to providing systematic products and services for scientific research, drug development, regenerative medicine, and personalized medical research and clinical applications. The business includes biological 3D printing systematic equipment, biomaterials and bio-inks, drug development tools for pharmaceutical companies, and treatment methods for patients with tissue and organ defects.

## Funding rounds

- Series B, Jul 2, 2018 — Puhua Capital
- Series B, Sep 7, 2017 — BICI Capital Fortune, Rise Sun Venture Capital, Heda Ventures
- Series A, Jun 25, 2015 — Share Capital, Five Bulls Fund, First Seafront Fund

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series A
- Five Bulls Fund — Series A
- First Seafront Fund — Series A
- BICI Capital Fortune (https://capitalatlas.ai/funds/bici-capital-fortune) — Series B
- Rise Sun Venture Capital (https://capitalatlas.ai/funds/rise-sun-venture-capital) — Series B
- Heda Ventures (https://capitalatlas.ai/funds/heda-ventures) — Series B
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series B